AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30

$2.13−0.01 (-0.47%)

Close on Nov 13, 2026Market cap $216.71MP/E –Yield –

AC Immune ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

AC Immune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACIU.

Revenue growth-86.9% · median -59.3%

Operating margin-1940.1% · median -1414.0%

Advertisement
300 × 250

See a number that looks wrong?